Prostate cancer vaccines in combination with additional treatment modalities (Q38212571)

31 August 2017

Prostate cancer vaccines in combination with additional treatment modalities (English)

1 reference

31 August 2017

1 reference

Matthew A Uhlman

1

1 reference

31 August 2017

Megan T Bing

series ordinal

2

1 reference

31 August 2017

David M Lubaroff

series ordinal

3

1 reference

31 August 2017

1 August 2014

1 reference

31 August 2017

1 reference

31 August 2017

59

1 reference

31 August 2017

1-3

1 reference

31 August 2017

236-242

1 reference

https://scigraph.springernature.com/pub.10.1007/s12026-014-8532-1

31 August 2017

0 references

cites work

Cancer statistics, 2014

1 reference

https://api.crossref.org/works/10.1007%2FS12026-014-8532-1

Global estimates of cancer prevalence for 27 sites in the adult population in 2008.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-014-8532-1

Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-014-8532-1

PSA progression following radical prostatectomy and radiation therapy: new standards in the new Millennium

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-014-8532-1

Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-014-8532-1

Metastatic prostate cancer-does treatment of the primary tumor matter?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-014-8532-1

Intermittent androgen suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-014-8532-1

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-014-8532-1

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-014-8532-1

Castrate-resistant prostate cancer: postdocetaxel management

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-014-8532-1

Abiraterone and increased survival in metastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-014-8532-1

Abiraterone in metastatic prostate cancer without previous chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-014-8532-1

Increased survival with enzalutamide in prostate cancer after chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-014-8532-1

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-014-8532-1

Interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-014-8532-1

Integrated safety data from 4 randomized, double-blind, controlled trials of autologous cellular immunotherapy with sipuleucel-T in patients with prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-014-8532-1

Sipuleucel-T immune parameters correlate with survival: an analysis of the randomized phase 3 clinical trials in men with castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-014-8532-1

Recent advances revolutionize treatment of metastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-014-8532-1

Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-014-8532-1

Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-014-8532-1

Harnessing the unique local immunostimulatory properties of modified vaccinia Ankara (MVA) virus to generate superior tumor-specific immune responses and antitumor activity in a diversified prime and boost vaccine regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-014-8532-1

Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-014-8532-1

Clinical protocol: phase I study of an adenovirus/prostate-specific antigen vaccine in men with metastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-014-8532-1

Phase I clinical trial of an adenovirus/prostate-specific antigen vaccine for prostate cancer: safety and immunologic results.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-014-8532-1

Cellular vaccine approaches

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-014-8532-1

Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase in patients with stage D0 prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-014-8532-1

DNA vaccine encoding prostatic acid phosphatase (PAP) elicits long-term T-cell responses in patients with recurrent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-014-8532-1

Induction of PSA-specific CTLs and anti-tumor immunity by a genetic prostate cancer vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-014-8532-1

6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-014-8532-1

Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-014-8532-1

Safety and immunologic response of a viral vaccine to prostate-specific antigen in combination with radiation therapy when metronomic-dose interleukin 2 is used as an adjuvant

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-014-8532-1

Long-term follow-up of prostate cancer patients treated with vaccine and definitive radiation therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-014-8532-1

CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-014-8532-1

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-014-8532-1

Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-014-8532-1

Analysis of overall survival in patients with nonmetastatic castration-resistant prostate cancer treated with vaccine, nilutamide, and combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-014-8532-1

Antiandrogen, vaccine and combination therapy in patients with nonmetastatic hormone refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-014-8532-1

Combining immunological and androgen-directed approaches: an emerging concept in prostate cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-014-8532-1

Combination of docetaxel and recombinant vaccine enhances T-cell responses and antitumor activity: effects of docetaxel on immune enhancement

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-014-8532-1

A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-014-8532-1

Immunotherapy for prostate cancer: walk, don't run.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-014-8532-1

Toward maximizing immunotherapy in metastatic castration-resistant prostate cancer - rationale for combinatorial approaches using chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-014-8532-1

A phase I trial of DNA vaccination with a plasmid expressing prostate-specific antigen in patients with hormone-refractory prostate cancer.

21 January 2018

1 reference

12 December 2020

Adenovirus infection enhances dendritic cell immunostimulatory properties and induces natural killer and T-cell-mediated tumor protection.

1 reference

12 December 2020

Samarium-153-EDTMP biodistribution and dosimetry estimation

1 reference

12 December 2020

Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial

1 reference

12 December 2020

Update on options for treatment of metastatic castration-resistant prostate cancer

1 reference

12 December 2020

New treatment options for castrate-resistant prostate cancer: a urology perspective.

1 reference

12 December 2020

Randomized trial of autologous cellular immunotherapy with sipuleucel-T in androgen-dependent prostate cancer

1 reference

12 December 2020

10.1007/S12026-014-8532-1

Identifiers

DOI

1 reference

Dimensions Publication ID

31 August 2017

0 references

1 reference